98%
921
2 minutes
20
Background: Obstructive sleep apnea (OSA) is a sleep disorder associated with an increased risk of cardiovascular and metabolic complications. Albuminuria, an early marker of kidney damage, is a proposed risk factor for OSA and its adverse outcomes. The study explored the association between OSA and albuminuria in Korean adults.
Methods: We screened participants from the cross-sectional Korean National Health and Nutrition Examination Survey (2019- 2021). The study included participants aged 40 years and older who completed the STOP-BANG questionnaire, a tool used to assess the OSA risk. Albuminuria was defined as a urine albumin-to-creatinine ratio ≥30 mg/g Cr. The participants were categorized based on albuminuria presence and severity. A multivariate logistic regression analysis examined the association between albuminuria and OSA.
Results: This study included 10,923 participants. Participants with albuminuria had significantly higher STOP-BANG scores than those without. Moreover, albuminuria remained strongly associated with an increased risk of OSA (odds ratio, 2.01; 95% confidence interval, 1.66-2.43), after multivariate adjustment. This association was more pronounced as albuminuria severity increased. Participants with high STOP-BANG scores were more likely to have albuminuria (odds ratio, 2.51; 95% confidence interval, 1.89-3.31), highlighting the bidirectional relationship between albuminuria and OSA.
Conclusion: The present study demonstrated a significant association between albuminuria and an elevated risk of OSA. These findings underscore the importance of early screening for OSA in patients with albuminuria, particularly in those with additional metabolic risk factors, to improve their long-term outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.23876/j.krcp.24.159 | DOI Listing |
Br J Cancer
September 2025
School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Background: Studies examining the association of chronic kidney disease (CKD) with cancer risk have demonstrated conflicting results.
Methods: This was an individual participant data meta-analysis including 54 international cohorts contributing to the CKD Prognosis Consortium. Included cohorts had data on albuminuria [urine albumin-to-creatinine ratio (ACR)], estimated glomerular filtration rate (eGFR), overall and site-specific cancer incidence, and established risk factors for cancer.
Cureus
August 2025
Internal Medicine, Russells Hall Hospital, Dudley, GBR.
Chronic kidney disease (CKD) poses a significant global health burden, with hyperuricemia emerging as a potential modifiable risk factor for disease progression. Urate-lowering agents (ULAs) have been hypothesized to preserve renal function by reducing serum uric acid (SUA) levels and mitigating associated pathogenic mechanisms. However, clinical evidence regarding their efficacy remains inconsistent.
View Article and Find Full Text PDFBMJ Open
September 2025
Renal and Metabolic Program, The George Institute for Global Health, Sydney, New South Wales, Australia
Objectives: Guideline-based strategies to prevent chronic kidney disease (CKD) progression and complications are available, yet their implementation in clinical practice is uncertain. We aimed to synthesise the available evidence on the concordance of CKD care with clinical guidelines to identify gaps and inform future CKD care.
Design: Systematic review and meta-analysis.
Kidney Int
August 2025
Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain; RICORS2040; Madrid, Spain; Departamento de Medicina, Facultad de Medicina, Universidad Autónoma de Madrid, 28049 Madrid, Spain. Electronic address:
Am J Cardiol
September 2025
Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. Electronic address:
AZD5462 is the first oral selective relaxin/insulin-like family peptide receptor 1 agonist in clinical development. The aim of this mechanistic study is to investigate the renal effects of AZD5462 when administered on top of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in participants with heart failure and moderate renal impairment. AURORA is a phase 1b, placebo-controlled, double-blind, 2-centre study of AZD5462 on top of dapagliflozin as standard of care in 2 arms.
View Article and Find Full Text PDF